Megan E. McNerney
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Megan E. McNerney has a total of 173 co-authors. Here are the top co-authors by number of shared publications:
- Michelle M. Le Beau
Arthur and Marian Edelstein Professor Emerita, Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois
11 shared publications - Ari J. Firestone
Calico Life Sciences LLC, South San Francisco, California
10 shared publications Elizabeth Davis
10 shared publications- James Downing
St. Jude Children's Research Hospital, Memphis, TN
10 shared publications - Joy Nakitandwe
Department of Pathology and Laboratory Medicine, Diagnostics Institute, Cleveland Clinic, Cleveland, OH
10 shared publications - Kevin M. Haigis
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA
10 shared publications
Latest Publications
- 11 December 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (24) , 2914-2930
CUX1 restrains latent hematopoietic stem cell plasticity by suppressing stem cell–intrinsic inflammatory pathways
Long-term maintenance of somatic stem cells relies on precise regulation of self-renewal and differentiation. Understanding the molecular framework for these homeostatic processes is essential for improved cellular therapies and treatment of myeloid neoplasms. CUX1 is a widely expressed, dosage-sensitive transcription factor crucial for development and frequently deleted in myeloid neoplasia in the context of –7/(del7q). Here, using novel mouse models and single-cell approaches, we report that dynamic and distinct CUX1 levels are integral to hematopoietic stem cell (HSC) activity. Knockdown of CUX1 reverses HSC differentiation and strikingly reendows progenitors with stem cell function, accompanied by restoration of the HSC transcriptome and DNA accessibility landscape. CUX1 mediates these activities, in part, via suppressing endogenous retroelements (EREs) and the ensuing interferon-stimulated gene expression program. Both EREs and the interferon response are upregulated in CUX1-deficient acute myeloid leukemia, suggesting a conserved role of CUX1 in regulating these elements. These data establish an unexpected entwinement between stem cell–intrinsic innate immune activation and the transcriptional programs of stem cell identity. Furthermore, we reveal the profound effects of transcription factor levels in cell fate.
- 11 December 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (24) , 2914-2930
CUX1 restrains latent hematopoietic stem cell plasticity by suppressing stem cell–intrinsic inflammatory pathways
Long-term maintenance of somatic stem cells relies on precise regulation of self-renewal and differentiation. Understanding the molecular framework for these homeostatic processes is essential for improved cellular therapies and treatment of myeloid neoplasms. CUX1 is a widely expressed, dosage-sensitive transcription factor crucial for development and frequently deleted in myeloid neoplasia in the context of –7/(del7q). Here, using novel mouse models and single-cell approaches, we report that dynamic and distinct CUX1 levels are integral to hematopoietic stem cell (HSC) activity. Knockdown of CUX1 reverses HSC differentiation and strikingly reendows progenitors with stem cell function, accompanied by restoration of the HSC transcriptome and DNA accessibility landscape. CUX1 mediates these activities, in part, via suppressing endogenous retroelements (EREs) and the ensuing interferon-stimulated gene expression program. Both EREs and the interferon response are upregulated in CUX1-deficient acute myeloid leukemia, suggesting a conserved role of CUX1 in regulating these elements. These data establish an unexpected entwinement between stem cell–intrinsic innate immune activation and the transcriptional programs of stem cell identity. Furthermore, we reveal the profound effects of transcription factor levels in cell fate.
- Open Access
- 19 May 2025
- Published by Elsevier in Blood Neoplasia
- Vol. 2 (3)
NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation
- 19 May 2025
- Published by Elsevier in Blood Neoplasia
- Vol. 2 (3)
Open AccessNAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation
- Open Access
- 3 March 2025
- Published by Elsevier in Blood Neoplasia
- Vol. 2 (2)
Multiplex gene editing models of del(7q) reveal combined CUX1 and EZH2 loss drives clonal expansion and drug resistance
- 3 March 2025
- Published by Elsevier in Blood Neoplasia
- Vol. 2 (2)
Open AccessMultiplex gene editing models of del(7q) reveal combined CUX1 and EZH2 loss drives clonal expansion and drug resistance
- Open Access
- 2 December 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (23)
YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production
The RNA N 6 -methyladenosine (m 6 A) reader YTHDF1 is implicated in cancer etiology and progression. We discovered that radiotherapy (RT) increased YTHDF1 expression in dendritic cells (DCs) of PBMCs from patients with cancer, but not in other immune cells tested. Elevated YTHDF1 expression in DCs was associated with poor outcomes for patients receiving RT. We found that loss of Ythdf1 in DCs enhanced the antitumor effects of ionizing radiation (IR) by increasing the cross-priming capacity of DCs across multiple murine cancer models. Mechanistically, IR upregulated YTHDF1 expression in DCs through stimulator of IFN genes/type I IFN (STING/IFN-I) signaling. YTHDF1 in turn triggered STING degradation by increasing lysosomal cathepsins, thereby reducing IFN-I production. We created a YTHDF1 deletion/inhibition prototype DC vaccine that significantly improved the therapeutic effect of RT and radioimmunotherapy in a murine melanoma model. Our findings reveal a layer of regulation between YTHDF1/m 6 A and STING in response to IR, which opens new paths for the development of YTHDF1-targeting therapies.
- 2 December 2024
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (23)
Open AccessYTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production
The RNA N 6 -methyladenosine (m 6 A) reader YTHDF1 is implicated in cancer etiology and progression. We discovered that radiotherapy (RT) increased YTHDF1 expression in dendritic cells (DCs) of PBMCs from patients with cancer, but not in other immune cells tested. Elevated YTHDF1 expression in DCs was associated with poor outcomes for patients receiving RT. We found that loss of Ythdf1 in DCs enhanced the antitumor effects of ionizing radiation (IR) by increasing the cross-priming capacity of DCs across multiple murine cancer models. Mechanistically, IR upregulated YTHDF1 expression in DCs through stimulator of IFN genes/type I IFN (STING/IFN-I) signaling. YTHDF1 in turn triggered STING degradation by increasing lysosomal cathepsins, thereby reducing IFN-I production. We created a YTHDF1 deletion/inhibition prototype DC vaccine that significantly improved the therapeutic effect of RT and radioimmunotherapy in a murine melanoma model. Our findings reveal a layer of regulation between YTHDF1/m 6 A and STING in response to IR, which opens new paths for the development of YTHDF1-targeting therapies.
- Open Access
- 11 May 2024
- Published by Elsevier in Cell Reports
- Vol. 43 (5) , 114227
CUX1 regulates human hematopoietic stem cell chromatin accessibility via the BAF complex
- 11 May 2024
- Published by Elsevier in Cell Reports
- Vol. 43 (5) , 114227
Open AccessCUX1 regulates human hematopoietic stem cell chromatin accessibility via the BAF complex
- Open Access
Real World Predictors of Response and 24-month survival in high-grade TP53-mutated Myeloid Neoplasms
Current therapies for high-grade TP53-mutated myeloid neoplasms (≥ 10% blasts) do not offer a meaningful survival benefit except allogeneic stem cell transplantation in the minority who achieve a complete response to first line therapy (CR1). To identify reliable pre-therapy predictors of response and outcomes, we assembled a cohort of 234 individuals with well-annotated clinical, molecular and pathology data, evaluating CR1 & 24-month survival (OS24). In this elderly cohort (median age 68.0 years) with 73.4% receiving frontline non-intensive regimens (hypomethylating agents with or without venetoclax), we identified several novel factors predictive of inferior CR1 including male gender (P = .019), ≥ 2 autosomal monosomies (P < .001), −17/17p (P = .008), multi-hit TP53 allelic state (P < .001) and CUX1 alterations (P = .009). Inferior OS24 was predicated by ≥ 2 monosomies (P = .004), TP53 VAF>25% (P < .001), and TP53 splice junction mutations (P = .007). In addition, mutations/deletions in any of six genes including CUX1, U2AF1, epigenetic regulators (EZH2, TET2), or RAS pathway genes (CBL, KRAS) (termed ‘EPI6’ signature) predicted inferior OS24 (HR = 2.0 [1.5–2.8]; P < .0001). A risk score incorporating these accessible binary factors in a multivariable model stratified 3 prognostic distinct groups: favorable, intermediate, and poor with significantly different median (15.4, 9.2, 3.5 months) and 24-month (48.4%, 14.3%, 0.5%) survival (OS24) (P < .0001). For the first time, in a seemingly monolithic high-risk cohort, our data provides means to tease out small subgroups at baseline with superior or very poor outcomes. Key Points ≥2 monosomies, multi-hit TP53 allelic state & CUX1 deletions are associated with poor frontline response in TP53-mutated myeloid neoplasm. TP53 VAF>25% and co-alterations in any one of six genes (CBL, CUX1, EZH2, KRAS, TET2 & U2AF1) adversely impact 24-month survival.
Open AccessReal World Predictors of Response and 24-month survival in high-grade TP53-mutated Myeloid Neoplasms
Current therapies for high-grade TP53-mutated myeloid neoplasms (≥ 10% blasts) do not offer a meaningful survival benefit except allogeneic stem cell transplantation in the minority who achieve a complete response to first line therapy (CR1). To identify reliable pre-therapy predictors of response and outcomes, we assembled a cohort of 234 individuals with well-annotated clinical, molecular and pathology data, evaluating CR1 & 24-month survival (OS24). In this elderly cohort (median age 68.0 years) with 73.4% receiving frontline non-intensive regimens (hypomethylating agents with or without venetoclax), we identified several novel factors predictive of inferior CR1 including male gender (P = .019), ≥ 2 autosomal monosomies (P < .001), −17/17p (P = .008), multi-hit TP53 allelic state (P < .001) and CUX1 alterations (P = .009). Inferior OS24 was predicated by ≥ 2 monosomies (P = .004), TP53 VAF>25% (P < .001), and TP53 splice junction mutations (P = .007). In addition, mutations/deletions in any of six genes including CUX1, U2AF1, epigenetic regulators (EZH2, TET2), or RAS pathway genes (CBL, KRAS) (termed ‘EPI6’ signature) predicted inferior OS24 (HR = 2.0 [1.5–2.8]; P < .0001). A risk score incorporating these accessible binary factors in a multivariable model stratified 3 prognostic distinct groups: favorable, intermediate, and poor with significantly different median (15.4, 9.2, 3.5 months) and 24-month (48.4%, 14.3%, 0.5%) survival (OS24) (P < .0001). For the first time, in a seemingly monolithic high-risk cohort, our data provides means to tease out small subgroups at baseline with superior or very poor outcomes. Key Points ≥2 monosomies, multi-hit TP53 allelic state & CUX1 deletions are associated with poor frontline response in TP53-mutated myeloid neoplasm. TP53 VAF>25% and co-alterations in any one of six genes (CBL, CUX1, EZH2, KRAS, TET2 & U2AF1) adversely impact 24-month survival.
- Open Access
- 24 January 2024
- Published by Annual Reviews in Annual Review of Pathology: Mechanisms of Disease
- Vol. 19 (1) , 571-598
Haploinsufficient Transcription Factors in Myeloid Neoplasms
Many transcription factors (TFs) function as tumor suppressor genes with heterozygous phenotypes, yet haploinsufficiency generally has an underappreciated role in neoplasia. This is no less true in myeloid cells, which are normally regulated by a delicately balanced and interconnected transcriptional network. Detailed understanding of TF dose in this circuitry sheds light on the leukemic transcriptome. In this review, we discuss the emerging features of haploinsufficient transcription factors (HITFs). We posit that: ( a) monoallelic and biallelic losses can have distinct cellular outcomes; ( b) the activity of a TF exists in a greater range than the traditional Mendelian genetic doses; and ( c) how a TF is deleted or mutated impacts the cellular phenotype. The net effect of a HITF is a myeloid differentiation block and increased intercellular heterogeneity in the course of myeloid neoplasia.
- 24 January 2024
- Published by Annual Reviews in Annual Review of Pathology: Mechanisms of Disease
- Vol. 19 (1) , 571-598
Open AccessHaploinsufficient Transcription Factors in Myeloid Neoplasms
Many transcription factors (TFs) function as tumor suppressor genes with heterozygous phenotypes, yet haploinsufficiency generally has an underappreciated role in neoplasia. This is no less true in myeloid cells, which are normally regulated by a delicately balanced and interconnected transcriptional network. Detailed understanding of TF dose in this circuitry sheds light on the leukemic transcriptome. In this review, we discuss the emerging features of haploinsufficient transcription factors (HITFs). We posit that: ( a) monoallelic and biallelic losses can have distinct cellular outcomes; ( b) the activity of a TF exists in a greater range than the traditional Mendelian genetic doses; and ( c) how a TF is deleted or mutated impacts the cellular phenotype. The net effect of a HITF is a myeloid differentiation block and increased intercellular heterogeneity in the course of myeloid neoplasia.